PACIRA PHARMACEUTICALS INC's ticker is PCRX and the CUSIP is 695127100. A total of 261 filers reported holding PACIRA PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 0.85 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,538,172 | -21.2% | 50,136 | +4.9% | 0.00% | 0.0% |
| Q2 2023 | $1,951,127 | 0.0% | 47,810 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $1,951,127 | +17.0% | 47,810 | +10.7% | 0.00% | 0.0% |
| Q4 2022 | $1,667,642 | -99.9% | 43,192 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $2,297,382,000 | -26.9% | 43,192 | -19.9% | 0.00% | -50.0% |
| Q2 2022 | $3,143,944,000 | -22.9% | 53,927 | +1.0% | 0.00% | 0.0% |
| Q1 2022 | $4,075,641,000 | +33.1% | 53,402 | +4.9% | 0.00% | +100.0% |
| Q4 2021 | $3,062,112,000 | +7.4% | 50,891 | 0.0% | 0.00% | 0.0% |
| Q3 2021 | $2,849,896,000 | -7.7% | 50,891 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $3,088,066,000 | -6.7% | 50,891 | +7.8% | 0.00% | 0.0% |
| Q1 2021 | $3,309,020,000 | +16.1% | 47,211 | -0.9% | 0.00% | 0.0% |
| Q4 2020 | $2,850,298,000 | +7.2% | 47,632 | +7.7% | 0.00% | 0.0% |
| Q3 2020 | $2,657,726,000 | +21.6% | 44,207 | +6.2% | 0.00% | 0.0% |
| Q2 2020 | $2,184,800,000 | +36.7% | 41,639 | -12.7% | 0.00% | 0.0% |
| Q1 2020 | $1,598,609,000 | -26.3% | 47,677 | -0.4% | 0.00% | 0.0% |
| Q4 2019 | $2,168,691,000 | +19.6% | 47,874 | +0.5% | 0.00% | 0.0% |
| Q3 2019 | $1,813,389,000 | -4.2% | 47,633 | +9.4% | 0.00% | 0.0% |
| Q2 2019 | $1,893,773,000 | +38.3% | 43,545 | +21.0% | 0.00% | 0.0% |
| Q1 2019 | $1,369,513,000 | -7.3% | 35,983 | +4.8% | 0.00% | 0.0% |
| Q4 2018 | $1,477,306,000 | +2.4% | 34,340 | +17.0% | 0.00% | 0.0% |
| Q3 2018 | $1,442,897,000 | +53.4% | 29,357 | 0.0% | 0.00% | 0.0% |
| Q2 2018 | $940,892,000 | +16.5% | 29,357 | +13.2% | 0.00% | 0.0% |
| Q1 2018 | $807,751,000 | -6.4% | 25,931 | +37.2% | 0.00% | 0.0% |
| Q4 2017 | $862,785,000 | -6.1% | 18,900 | -22.7% | 0.00% | 0.0% |
| Q3 2017 | $918,623,000 | -20.3% | 24,464 | +1.2% | 0.00% | 0.0% |
| Q2 2017 | $1,153,004,000 | -85.6% | 24,172 | -86.2% | 0.00% | -87.5% |
| Q1 2017 | $7,993,314,000 | +144890.3% | 175,292 | +2.7% | 0.01% | +33.3% |
| Q4 2016 | $5,513,000 | -16.1% | 170,700 | -11.1% | 0.01% | -14.3% |
| Q3 2016 | $6,573,000 | -1.4% | 192,090 | -2.8% | 0.01% | -12.5% |
| Q2 2016 | $6,665,000 | -5.6% | 197,606 | +48.2% | 0.01% | 0.0% |
| Q1 2016 | $7,063,000 | -35.8% | 133,322 | -6.9% | 0.01% | -38.5% |
| Q4 2015 | $10,995,000 | +162.7% | 143,190 | +40.6% | 0.01% | +160.0% |
| Q3 2015 | $4,186,000 | -31.2% | 101,836 | +18.3% | 0.01% | -16.7% |
| Q2 2015 | $6,085,000 | -20.4% | 86,058 | +0.1% | 0.01% | -14.3% |
| Q1 2015 | $7,641,000 | -0.4% | 85,999 | -0.6% | 0.01% | 0.0% |
| Q4 2014 | $7,669,000 | +6.8% | 86,499 | +16.7% | 0.01% | 0.0% |
| Q3 2014 | $7,182,000 | +4.5% | 74,099 | -0.9% | 0.01% | 0.0% |
| Q2 2014 | $6,870,000 | +20.6% | 74,799 | -8.1% | 0.01% | +16.7% |
| Q1 2014 | $5,697,000 | +16.2% | 81,399 | -4.6% | 0.01% | 0.0% |
| Q4 2013 | $4,904,000 | -40.8% | 85,299 | -50.5% | 0.01% | -40.0% |
| Q3 2013 | $8,281,000 | +78.0% | 172,199 | +7.4% | 0.01% | +66.7% |
| Q2 2013 | $4,651,000 | – | 160,399 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gagnon Advisors, LLC | 251,140 | $19,167,000 | 8.83% |
| GAGNON SECURITIES LLC | 610,933 | $46,626,000 | 7.60% |
| Tamarack Advisers, LP | 205,000 | $15,646,000 | 7.40% |
| Spyglass Capital Management LLC | 1,871,040 | $142,798,000 | 4.88% |
| Lisanti Capital Growth, LLC | 302,413 | $23,080,000 | 2.59% |
| Rock Springs Capital Management LP | 1,000,000 | $76,320,000 | 1.92% |
| MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 208,197 | $15,890,000 | 1.76% |
| JABODON PT CO | 49,052 | $3,744,000 | 1.70% |
| Zweig-DiMenna Associates LLC | 166,675 | $12,721,000 | 1.70% |
| NEUMEIER POMA INVESTMENT COUNSEL LLC | 317,425 | $24,226,000 | 1.63% |